{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:47:54Z","timestamp":1782280074174,"version":"3.54.5"},"posted":{"date-parts":[[2025,4,8]]},"group-title":"Pharmacology and Toxicology","reference-count":87,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Mineralocorticoid receptor (MR) overactivation plays a crucial role in the pathogenesis of chronic kidney disease, as well as several cardiovascular and arterial diseases. Current studies determined the mechanisms of the beneficial kidney effects of the non-steroidal MR antagonist Finerenone (FN) in a mouse model of western diet-induced obesity and insulin resistance. 10-week-old male C57BL\/6J mice were fed a low fat (LF) or a western diet (WD) for 12 weeks followed by treatment with either vehicle or finerenone (FN) for another 14 weeks (intervention studies) until they were 36 weeks old. Finerenone treatment prevented a) the increased albuminuria and kidney injury molecule 1 (KIM1), b) the expanded extracellular mesangial matrix, and podocyte injury, c) fibronectin, collagen IV, CD45 and CD68 immunostaining, d) glomerular basement membrane disruption, podocyte foot process loss, and mitochondrial structural abnormalities, e) the pro-inflammatory cytokines (MCP1), innate immunity pathways (TLR2, STING, STAT3), and fibrosis markers fibronectin, TGF\u03b2 and Pai1, and f) the increased kidney cholesterol levels. There was also reduced expression of nuclear receptor ERR\u03b3 without changes in ERR\u03b1 in WD-fed mice whereas both ERR\u03b1 and ERR\u03b3 expression levels increased after Finerenone treatment. NADH lifetime analysis showed decreased bound NADH, compatible with decreased mitochondrial OXPHOS in the kidneys of WD-fed mice compared to controls, which was prevented by finerenone treatment. In conclusion, Finerenone treatment exhibits a renal protective role and prevents the progression of kidney disease by regulating mitochondrial function, most likely via ERR\u03b3, and reducing lipid accumulation and inflammation.<\/jats:p>","DOI":"10.1101\/2025.04.02.646892","type":"posted-content","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T19:45:11Z","timestamp":1744141511000},"source":"Crossref","is-referenced-by-count":0,"title":["The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-047X","authenticated-orcid":false,"given":"Komuraiah","family":"Myakala","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-6228","authenticated-orcid":false,"given":"Xiaoxin X.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Shults","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"},{"name":"Department of Pathology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-2615","authenticated-orcid":false,"given":"Eleni P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia de Carvalho","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozhin","family":"Penjweini","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Microscopy and Biophotonics, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Link","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Microscopy and Biophotonics, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3874-9754","authenticated-orcid":false,"given":"Keely","family":"Barton","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-9720","authenticated-orcid":false,"given":"Ewa","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"},{"name":"Department of Pathology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Clarkson Paredes","sequence":"additional","affiliation":[{"name":"GW Nanofabrication and Imaging Center (GWNIC), George Washington University, Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastas","family":"Popratiloff","sequence":"additional","affiliation":[{"name":"GW Nanofabrication and Imaging Center (GWNIC), George Washington University, Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-1738","authenticated-orcid":false,"given":"Jay R.","family":"Knutson","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Microscopy and Biophotonics, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5312-5232","authenticated-orcid":false,"given":"Ashley L","family":"Cowart","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6403-2261","authenticated-orcid":false,"given":"Moshe","family":"Levi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA"},{"name":"Center for Biomedical and Biological Engineering, Georgetown, Washington DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026041203253508000_2025.04.02.646892v2.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"2026041203253508000_2025.04.02.646892v2.2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116"},{"key":"2026041203253508000_2025.04.02.646892v2.3","doi-asserted-by":"publisher","DOI":"10.3390\/kidneydial2030038"},{"key":"2026041203253508000_2025.04.02.646892v2.4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11892-018-0980-x","article-title":"The Landscape of Diabetic Kidney Disease in the United States","volume":"18","year":"2018","journal-title":"Curr Diab Rep"},{"key":"2026041203253508000_2025.04.02.646892v2.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61350-6"},{"key":"2026041203253508000_2025.04.02.646892v2.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03555-0"},{"key":"2026041203253508000_2025.04.02.646892v2.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100624"},{"key":"2026041203253508000_2025.04.02.646892v2.8","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00583-y"},{"key":"2026041203253508000_2025.04.02.646892v2.9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12882-019-1220-6","article-title":"Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study","volume":"20","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026041203253508000_2025.04.02.646892v2.10","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S39739"},{"key":"2026041203253508000_2025.04.02.646892v2.11","first-page":"1095211","article-title":"Obesity-related kidney disease: Beyond hypertension and insulin-resistance","volume":"13","year":"2022","journal-title":"Front Endocrinol (Lausanne"},{"key":"2026041203253508000_2025.04.02.646892v2.12","first-page":"58","article-title":"Oxidative stress in obesity and insulin resistance","volume":"3","year":"2022","journal-title":"Exploration of Medicine"},{"key":"2026041203253508000_2025.04.02.646892v2.13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms12053117"},{"key":"2026041203253508000_2025.04.02.646892v2.14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15518"},{"key":"2026041203253508000_2025.04.02.646892v2.15","doi-asserted-by":"publisher","DOI":"10.2337\/cd21-0090"},{"key":"2026041203253508000_2025.04.02.646892v2.16","doi-asserted-by":"crossref","unstructured":"Trillini M , and Ruggenenti P . The risk of CKD progression remains high in patients treated with ACE inhibitors and ARBs, MRAs and SGLT2 inhibitors. Have we already achieved the therapeutic ceiling in CKD? (The CON part). Clinical Kidney Journal 17: 2024.","DOI":"10.1093\/ckj\/sfae015"},{"key":"2026041203253508000_2025.04.02.646892v2.17","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32835bf7b0"},{"key":"2026041203253508000_2025.04.02.646892v2.18","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K06-025"},{"key":"2026041203253508000_2025.04.02.646892v2.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2018.01.017"},{"key":"2026041203253508000_2025.04.02.646892v2.20","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12032"},{"key":"2026041203253508000_2025.04.02.646892v2.21","doi-asserted-by":"crossref","first-page":"100349","DOI":"10.1016\/j.jacadv.2023.100349","article-title":"Individuals With Chronic Kidney Disease Qualifying for SGLT-2 Inhibitors in the United States and EMPA-KIDNEY Generalizability","volume":"2","year":"2023","journal-title":"JACC Adv"},{"key":"2026041203253508000_2025.04.02.646892v2.22","doi-asserted-by":"crossref","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026041203253508000_2025.04.02.646892v2.23","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00135.2024"},{"key":"2026041203253508000_2025.04.02.646892v2.24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3803\/EnM.2022.1629","article-title":"Renal Protection of Mineralocorticoid Receptor Antagonist","volume":"38","year":"2023","journal-title":"Finerenone, in Diabetic Kidney Disease. Endocrinol Metab (Seoul"},{"key":"2026041203253508000_2025.04.02.646892v2.25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18360"},{"key":"2026041203253508000_2025.04.02.646892v2.26","doi-asserted-by":"crossref","first-page":"754239","DOI":"10.3389\/fphar.2021.754239","article-title":"Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease","volume":"12","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026041203253508000_2025.04.02.646892v2.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"2026041203253508000_2025.04.02.646892v2.28","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/s41598-018-21087-5","article-title":"Vascular dysfunction in obese diabetic db\/db mice involves the interplay between aldosterone\/mineralocorticoid receptor and Rho kinase signaling","volume":"8","year":"2018","journal-title":"Sci Rep"},{"key":"2026041203253508000_2025.04.02.646892v2.29","doi-asserted-by":"crossref","first-page":"e21314","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","year":"2021","journal-title":"FASEB J"},{"key":"2026041203253508000_2025.04.02.646892v2.30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00313"},{"key":"2026041203253508000_2025.04.02.646892v2.31","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0294"},{"key":"2026041203253508000_2025.04.02.646892v2.32","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0007072021"},{"key":"2026041203253508000_2025.04.02.646892v2.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03264-4"},{"key":"2026041203253508000_2025.04.02.646892v2.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.004"},{"key":"2026041203253508000_2025.04.02.646892v2.35","doi-asserted-by":"crossref","unstructured":"Jerome JR , Deliyanti D , Suphapimol V , Kolkhof P , and Wilkinson-Berka JL . Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy. Int J Mol Sci 24: 2023.","DOI":"10.3390\/ijms24032334"},{"key":"2026041203253508000_2025.04.02.646892v2.36","doi-asserted-by":"publisher","DOI":"10.1159\/000518254"},{"key":"2026041203253508000_2025.04.02.646892v2.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00490-8"},{"key":"2026041203253508000_2025.04.02.646892v2.38","doi-asserted-by":"crossref","unstructured":"Abedini A , Sanchez-Navaro A , Wu J , Klotzer KA , Ma Z , Poudel B , Doke T , Balzer MS , Frederick J , Cernecka H , Liu H , Liang X , Vitale S , Kolkhof P , and Susztak K . Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists. J Clin Invest 134: 2024.","DOI":"10.1172\/JCI157165"},{"key":"2026041203253508000_2025.04.02.646892v2.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107"},{"key":"2026041203253508000_2025.04.02.646892v2.40","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0944"},{"key":"2026041203253508000_2025.04.02.646892v2.41","doi-asserted-by":"crossref","unstructured":"Ferreira JP , Oliveira AC , Vasques-Novoa F , Leite AR , Mendonca L , Zannad F , Butler J , Leite-Moreira A , Saraiva F , and Neves JS . Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials. Am J Nephrol 1\u20137, 2024.","DOI":"10.1159\/000541686"},{"key":"2026041203253508000_2025.04.02.646892v2.42","doi-asserted-by":"crossref","unstructured":"Kolkhof P , Lawatscheck R , Filippatos G , and Bakris GL . Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci 23: 2022.","DOI":"10.3390\/ijms23169243"},{"key":"2026041203253508000_2025.04.02.646892v2.43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress","volume":"9","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026041203253508000_2025.04.02.646892v2.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076444"},{"key":"2026041203253508000_2025.04.02.646892v2.45","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","article-title":"Finerenone Added to RAS\/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-\/- Mice","volume":"34","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026041203253508000_2025.04.02.646892v2.46","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000164R"},{"key":"2026041203253508000_2025.04.02.646892v2.47","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00068.2011"},{"key":"2026041203253508000_2025.04.02.646892v2.48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11906-014-0529-6","article-title":"The Western Diet and Chronic Kidney Disease","volume":"17","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"2026041203253508000_2025.04.02.646892v2.49","doi-asserted-by":"publisher","DOI":"10.5487\/TR.2014.30.1.007"},{"key":"2026041203253508000_2025.04.02.646892v2.50","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(88)90023-8"},{"key":"2026041203253508000_2025.04.02.646892v2.51","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00614.2020"},{"key":"2026041203253508000_2025.04.02.646892v2.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104975"},{"key":"2026041203253508000_2025.04.02.646892v2.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113459"},{"key":"2026041203253508000_2025.04.02.646892v2.54","first-page":"342","article-title":"Glomerular basement membrane thickness in an Asian population using a novel image analysis software","volume":"41","year":"2009","journal-title":"Pathology"},{"key":"2026041203253508000_2025.04.02.646892v2.55","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080752"},{"key":"2026041203253508000_2025.04.02.646892v2.56","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.30.1.23"},{"key":"2026041203253508000_2025.04.02.646892v2.57","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/photonics9050294","article-title":"Intravital Imaging with Two-Photon Microscopy: A Look into the Kidney","volume":"9","year":"2022","journal-title":"Photonics"},{"key":"2026041203253508000_2025.04.02.646892v2.58","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016030349"},{"key":"2026041203253508000_2025.04.02.646892v2.59","doi-asserted-by":"crossref","first-page":"925619","DOI":"10.3389\/fnut.2022.925619","article-title":"Obesity-Related Chronic Kidney Disease: Principal Mechanisms and New Approaches in Nutritional Management","volume":"9","year":"2022","journal-title":"Front Nutr"},{"key":"2026041203253508000_2025.04.02.646892v2.60","doi-asserted-by":"crossref","unstructured":"Crompton M , Ferguson JK , Ramnath RD , Onions KL , Ogier AS , Gamez M , Down CJ , Skinner L , Wong KH , Dixon LK , Sutak J , Harper SJ , Pontrelli P , Gesualdo L , Heerspink HL , Toto RD , Welsh GI , Foster RR , Satchell SC , and Butler MJ . Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight 8: 2023.","DOI":"10.1172\/jci.insight.154164"},{"key":"2026041203253508000_2025.04.02.646892v2.61","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M500801200"},{"key":"2026041203253508000_2025.04.02.646892v2.62","doi-asserted-by":"publisher","DOI":"10.1038\/srep16474"},{"key":"2026041203253508000_2025.04.02.646892v2.63","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.462"},{"key":"2026041203253508000_2025.04.02.646892v2.64","doi-asserted-by":"crossref","unstructured":"Wang D , Luo Y , Wang X , Orlicky DJ , Myakala K , Yang P , and Levi M . The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice. Int J Mol Sci 19: 2018.","DOI":"10.3390\/ijms19010137"},{"key":"2026041203253508000_2025.04.02.646892v2.65","doi-asserted-by":"crossref","first-page":"115166","DOI":"10.1016\/j.biopha.2023.115166","article-title":"Novel insights into STAT3 in renal diseases","volume":"165","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026041203253508000_2025.04.02.646892v2.66","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00034.2019"},{"key":"2026041203253508000_2025.04.02.646892v2.67","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00203.2019"},{"key":"2026041203253508000_2025.04.02.646892v2.68","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41419-020-03122-4","article-title":"High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial dysfunction","volume":"11","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026041203253508000_2025.04.02.646892v2.69","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.22-73"},{"key":"2026041203253508000_2025.04.02.646892v2.70","doi-asserted-by":"publisher","DOI":"10.1364\/BOE.7.001690"},{"key":"2026041203253508000_2025.04.02.646892v2.71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108161108"},{"key":"2026041203253508000_2025.04.02.646892v2.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.02.019"},{"key":"2026041203253508000_2025.04.02.646892v2.73","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41581-020-00337-8","article-title":"Advances in fluorescence microscopy techniques to study kidney function","volume":"17","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2026041203253508000_2025.04.02.646892v2.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2023.07.008"},{"key":"2026041203253508000_2025.04.02.646892v2.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.11.011"},{"key":"2026041203253508000_2025.04.02.646892v2.76","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","article-title":"Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db\/db Mice","volume":"78","year":"2021","journal-title":"Hypertension"},{"key":"2026041203253508000_2025.04.02.646892v2.77","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.114"},{"key":"2026041203253508000_2025.04.02.646892v2.78","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone\u2014Translational Aspects and Clinical Perspectives across Multiple Organ Systems","volume":"23","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"2026041203253508000_2025.04.02.646892v2.79","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000091"},{"key":"2026041203253508000_2025.04.02.646892v2.80","doi-asserted-by":"crossref","unstructured":"Lu J , Li XQ , Chen PP , Zhang JX , Liu L , Wang GH , Liu XQ , Jiang TT , Wang MY , Liu WT , Ruan XZ , and Ma KL . Activation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy. JCI Insight 8: 2023.","DOI":"10.1172\/jci.insight.165817"},{"key":"2026041203253508000_2025.04.02.646892v2.81","doi-asserted-by":"crossref","unstructured":"Di Lullo L , Lavalle C , Scatena A , Mariani MV , Ronco C , and Bellasi A . Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. J Clin Med 12: 2023.","DOI":"10.3390\/jcm12123992"},{"key":"2026041203253508000_2025.04.02.646892v2.82","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050757"},{"key":"2026041203253508000_2025.04.02.646892v2.83","doi-asserted-by":"crossref","first-page":"102946","DOI":"10.1016\/j.redox.2023.102946","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy","volume":"68","year":"2023","journal-title":"Redox Biol"},{"key":"2026041203253508000_2025.04.02.646892v2.84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1804965115"},{"key":"2026041203253508000_2025.04.02.646892v2.85","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.24.10684-10694.2005"},{"key":"2026041203253508000_2025.04.02.646892v2.86","doi-asserted-by":"crossref","unstructured":"Juszczak F , Caron N , Mathew AV , and Decleves AE . Critical Role for AMPK in Metabolic Disease-Induced Chronic Kidney Disease. Int J Mol Sci 21: 2020.","DOI":"10.3390\/ijms21217994"},{"key":"2026041203253508000_2025.04.02.646892v2.87","doi-asserted-by":"publisher","DOI":"10.1096\/fba.2022-00015"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.04.02.646892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:56:22Z","timestamp":1782276982000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.04.02.646892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":87,"URL":"https:\/\/doi.org\/10.1101\/2025.04.02.646892","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1152\/ajprenal.00136.2025","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,4,8]]},"subtype":"preprint"}}